Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

employees Ranked by 2024 Massachusetts gross residential sales volume from closed transactions JuliaHub is doubling its investment in the pharmaceutical ... Join the Boston Business Journal ...

Strategically located near the Boston pharmaceutical and biotech hub, Veranova’s Devens site is an FDA approved facility and a center of excellence for development through clinical and commercial ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

No Shareholder Action is Required at this TimeBOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: ...

currently with Boston Pharmaceuticals and Pfizer, which also involve 4-1BB bispecific proteins. Pfizer is developing SGN-BB228, a CD228/4-1BB candidate it inherited as part of its takeover of ...

PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Jazz Pharmaceuticals, a Zacks Rank #1 (Strong Buy), is a specialty biopharmaceutical company that identifies, develops, and commercializes pharmaceutical products in the United States, Europe ...